Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS

Next Previous
Search
Trial Profile

EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PROPEL
  • Sponsors Pfizer

    • Most Recent Events

    • 03 Jun 2023 Post hoc analysis results presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 03 Jun 2023 Results assessing relationship between changes in gene expression and treatment response in patients with JIA treated with tofacitinib, presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 14 Nov 2022 Results (n=166) assessing to test the usefulness of candidate blood-based biomarkers (CBB) previously associated with status and course of JIA or rheumatoid arthritis for prediction of JIA disease activity and improvement after 18 weeks of tofacitinib use, presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top